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Introduction: We conducted a phase II study of dual-agent mono-
clonal antibody therapy consisting of cetuximab and bevacizumab in 
combination with paclitaxel and carboplatin chemotherapy in non–
small-cell lung cancer.
Methods:Patients with stage IIIB/IV nonsquamous non–small-cell 
lung cancer randomly received cetuximab (400 mg/m2 initially, 250 mg/
m2 weekly thereafter) plus bevacizumab (15 mg/kg) for six cycles com-
bined with paclitaxel (200 mg/m2) and carboplatin (area under the curve 
6) for either six cycles (six-cycle arm) or the first three cycles (three-
cycle arm) (one cycle = 3 weeks). The primary objective was progres-
sion-free survival (PFS), estimated separately for each treatment arm.
Results:In 121 patients, the median PFS was 6.05 months (95% 
confidence interval [CI]: 5.65, 7.03) in the six-cycle arm and 4.50 
months (95% CI: 4.01, 5.42) in the three-cycle arm. Respective 
median overall survival times were 12.06 months (95% CI: 9.40, 
19.25) and 11.63 months (95% CI: 6.64, 17.61). The tumor response 
rate was 51.7% (95% CI: 39.0%, 64.3%) and 44.3% (95% CI: 31.8%, 
56.7%) in the six-cycle and three-cycle arms, respectively, with cor-
responding median response durations of 4.86 months (95% CI: 
4.30, 7.16) and 3.94 months (95% CI: 2.92, 4.47). Quality of life 
was consistent across arms. Cetuximab-related grade 3/4 events in 
greater than 5% of patients (six-cycle arm, three-cycle arm) were 
dermatitis acneiform (6.9%; 8.6%) and fatigue (13.8%; 5.2%). Three 
patients died during the study from drug-related adverse events (one 
in the six-cycle arm and two in the three-cycle arm).
Conclusions: Both the regimens showed expected PFS and numeri-
cally comparable overall survival. Quality of life was similar in the 
two arms, and both the regimens were well tolerated.
Key Words: Bevacizumab, Carboplatin, Cetuximab, Non–small-cell 
lung cancer, Paclitaxel.
(J Thorac Oncol. 2013;8: 338–345)
Lung cancer accounts for about 28% of cancer deaths, more deaths than any other cancer. Non–small-cell lung cancer 
(NSCLC) accounts for 75 to 80% of all lung cancers1 and is 
unresectable in 80% of cases.2 Platinum-based doublets, such 
as paclitaxel and carboplatin, are the standard chemotherapy 
currently approved by regulatory authorities for the treatment 
of NSCLC. With none of the chemotherapy doublets show-
ing survival superiority in unselected patients, investigators 
began testing novel agents in combination with chemotherapy 
doublets. Superior survival was observed with paclitaxel–
carboplatin combined with a monoclonal antibody targeting 
vascular endothelial growth factor (bevacizumab) compared 
with chemotherapy alone.3 At the time the trial described in 
this report was being planned, randomized phase II studies 
showed higher response rates (RRs) and a trend for superior 
survival for platinum doublets combined with cetuximab,4,5 
and acceptable toxicity was observed in a phase I/II study of 
paclitaxel–carboplatin and cetuximab.6
These observations served as the basis for our phase 
II randomized study, which was designed to determine the 
efficacy and safety of dual-agent monoclonal antibody therapy 
consisting of cetuximab and bevacizumab in combination 
with paclitaxel and carboplatin chemotherapy in patients with 
advanced nonsquamous NSCLC. Another objective of this 
trial was to explore the possibility of reducing the toxicity 
of cytotoxic therapy by reducing the number of courses of 
the platinum doublet while retaining efficacy. Although two 
randomized trials had shown similar overall survival (OS) in 
patients treated with three versus six cycles of platinum-based 
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combination regimens,7,8 the optimum number of courses of a 
platinum doublet in combination with cetuximab, bevacizumab, 
or both was unknown. Therefore, we decided to explore three 
versus six courses of paclitaxel and carboplatin in combination 
with cetuximab and bevacizumab. Based on the potential for 
synergy between cetuximab and bevacizumab, we initially 
considered comparing the monoclonal antibody doublet with 
or without chemotherapy. However, we decided that it would 
not be appropriate to exclude conventional first-line therapy. 
In addition, we decided to discontinue bevacizumab after six 
cycles because we suspected that the survival benefit seen with 
bevacizumab combined with paclitaxel–carboplatin occurred 
while patients were receiving the agents simultaneously. 
Our rationale was based on preclinical observations, which 
showed that bevacizumab normalizes tumor blood vessels and 
reduces interstitial pressure within tumors. This phenomenon is 
associated with increased drug concentration within tumors9,10 
and may be the primary reason for superior survival that was 
observed when bevacizumab was combined with paclitaxel–
carboplatin.3 We continued bevacizumab for six cycles in 
both the arms so the treatment variables would be limited to 
duration of chemotherapy. In addition, the high cost of long-
term treatment with bevacizumab was considered in our study 
design.
During the study enrollment, a randomized phase III 
trial showed a statistically significant improvement in sur-
vival for cetuximab when added to vinorelbine–cisplatin for 
the first-line treatment of NSCLC.11 A second phase III trial 
showed a similar magnitude of survival improvement for 
cetuximab with taxane (paclitaxel or docetaxel) and carbopla-
tin, although this study did not meet its primary end point of 
progression-free survival (PFS).12
PATIENTS AND METHODS
Eligibility Criteria
Patients were chemotherapy- and/or radiation therapy-
naive men or women aged 18 years or older with histologi-
cally or cytologically confirmed advanced (stage IIIB with 
malignant pleural effusion, stage IV, or recurrent) nonsqua-
mous NSCLC. All patients were to have measurable disease 
as defined by Response Evaluation Criteria in Solid Tumors, 
adequate organ function (including adequate hematologic, 
hepatic, and renal function), and an Eastern Cooperative 
Oncology Group performance status of 0 or 1. Ineligibility 
criteria included ongoing or active infection; symptomatic 
congestive heart failure, unstable angina pectoris, or cardiac 
arrhythmia; history of thrombotic or hemorrhagic disorders; 
history of gross hemoptysis; preexisting neuropathy grade 
1 or more; known central nervous system metastases; and 
uncontrolled hypertension (>150/100 mmHg) on a standard 
regimen of antihypertensive therapy. Chronic daily treatment 
with aspirin (>325 mg/day) and/or nonsteroidal anti-inflam-
matory agents known to inhibit platelet function, anticoagu-
lation therapy, and treatment with dipyridamole, ticlopidine, 
clopidogrel, and/or cilostazol were not allowed. Patients with 
serious nonhealing wound ulcer, bone fracture, or major surgi-
cal procedure within 30 days before the first dose or elective 
or planned major surgery to be performed during the course of 
the trial were also ineligible.
The study was approved by ethical/institutional review 
boards and was conducted in accordance with the Declaration 
of Helsinki and good clinical practices. All patients provided 
signed informed consent.
Study Design and Treatment Plan
The primary objective of this multicenter, open-label, 
randomized, phase II study was to estimate PFS separately for 
each treatment arm. Secondary objectives included estimation 
of OS, tumor RR, duration of response, safety and tolerability, 
quality-of-life (QoL) assessment, and analysis of tumor tis-
sue, if available, for epidermal growth factor receptor (EGFR) 
expression for each treatment arm. A monoclonal antibody 
was used to determine the EGFR expression, and slides were 
reviewed by a pathologist. If any cells showed staining, speci-
mens were classified as positive, and positivity was defined as 
0 versus 1+ versus 2+ versus 3+. H scores and EGFR mutation 
analyses were not performed.
Patients were randomized (1:1 ratio) to receive cetux-
imab and bevacizumab plus paclitaxel and carboplatin for 
six cycles (six-cycle arm) or cetuximab and bevacizumab for 
six cycles in combination with paclitaxel and carboplatin for 
the first three cycles (three-cycle arm). Cetuximab (ImClone 
Systems, Bridgewater, NJ) 250 mg/m2 was administered intra-
venously (i.v.) weekly over 60 minutes, after an initial dose of 
400 mg/m2 over 120 minutes on day 1, in each 3-week cycle 
for six cycles. Bevacizumab 15 mg/kg was administered i.v. 
over 90 minutes on day 8 (after the cetuximab infusion) of 
each 3-week cycle for six cycles. Paclitaxel 200 mg/m2 was 
administered i.v. over 3 hours followed by carboplatin area 
under the curve 6 i.v. over 30 minutes on day 1 of each 3-week 
cycle for either six cycles (six-cycle arm) or the first three 
cycles (three-cycle arm) (Fig. 1). Combination therapy of 
up to six cycles was continued in the absence of progressive 
disease (PD) or other withdrawal criteria. Patients who dem-
onstrated complete response (CR), partial response (PR), or 
stable disease after six cycles of therapy in either treatment 
arm may have continued on cetuximab monotherapy until PD 
or other withdrawal criteria were met.
All patients were premedicated with diphenhydramine 
hydrochloride, 50 mg oral or i.v. (or a similar agent) before 
the first dose of cetuximab in an effort to prevent an infusion 
reaction and at subsequent doses at the investigator’s discre-
tion. Before each infusion of paclitaxel, all patients were pre-
medicated with oral dexamethasone 20 mg (or i.v. equivalent) 
as well as an antihistamine (H1 antagonist) and cimetidine 
300 mg i.v. Antiemetics should have been given in conjunction 
with carboplatin as well as therapy for prevention of delayed 
emesis.
Cetuximab and bevacizumab infusions were not delayed 
or discontinued for chemotherapy-related toxicities, nor was 
chemotherapy delayed or discontinued for cetuximab- or 
bevacizumab-related toxicities. Cetuximab was discontinued 
for a grade 3 or 4 infusion reaction, a grade 4 acneiform rash 
that did not improve after a 3-week delay, a second cetuximab 
infusion reaction after a 50% reduction in infusion rate, or a 
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lack of recovery from toxicity longer than 3 weeks from the 
next scheduled dose. Chemotherapy and/or bevacizumab was 
discontinued for a lack of recovery from a toxicity longer 
than 3 weeks from the next scheduled dose of paclitaxel or 
carboplatin.
Baseline and Treatment Assessments
Physical examinations, weight measurements, hematol-
ogy and chemistry tests, urinalysis, and Eastern Cooperative 
Oncology Group performance status were assessed at baseline 
and before every cycle. Electrocardiograms were performed 
at baseline. Weekly evaluations during the study included 
vital sign measurements and toxicity evaluations (classified 
by Medical Dictionary for Regulatory Activities and graded 
by National Cancer Institute Common Terminology Criteria 
for Adverse Events version 3.0). Imaging studies (computed 
tomography or magnetic resonance imaging) were performed 
at baseline and every 6 weeks or more.
PFS was defined as the time from randomization until 
the date of PD or death from any cause. OS was defined as the 
time from randomization to death. Tumor RR was evaluated 
according to a modified version of the Response Evaluation 
Criteria in Solid Tumors 1.0 guidelines.13 Duration of response 
was defined as the time measurement criteria were met for 
CR/PR until the first date of PD or death. Patients who were 
alive and without progression were censored at the day of their 
last tumor assessment.
QoL was assessed at baseline and every 6 weeks using 
the seven-item Lung Cancer Subscale (LCS) of the Functional 
Assessment of Cancer Treatment-Lung (FACT-L), and 
Functional Assessment of Cancer Therapy-Lung Symptom 
Index-12 (FLSI-12). The FACT-LCS is a validated set of seven 
items developed to measure lung cancer symptoms. Patients 
respond to each item on a five-point Likert-type scale from 
zero (not at all) to four (very much). Scoring was according 
to the LCS Scoring Manual version 4.0.14 A higher score indi-
cates fewer symptoms, ranging from zero (severely symp-
tomatic in all symptoms assessed) to 28 (symptom free on all 
symptoms assessed). Symptom response (improvement) was 
defined as a two-point or more point increase, whereas symp-
tom progression (deterioration) was defined as a two-point or 
more point decrease from baseline that was maintained for two 
consecutive assessments at least 3 weeks and not longer than 
5 weeks, apart. The trial outcome index (TOI), defined as the 
combined total of the physical and functional well-being sub-
scales of the FACT-L and the seven-item LCS, was also sum-
marized. FLSI-12 is a new questionnaire that adds five items 
to the seven items in the LCS to document patient tolerability 
to treatment and overall QoL. The minimally important differ-
ence in this scale is three to four points. Scoring was accord-
ing to the published Functional Assessment of Chronic Illness 
Therapy Scoring Manual.15
Statistical Considerations
The primary end point of this trial was a noncomparative 
estimate of PFS, and secondary end points were also 
noncomparative estimate of response, OS, evaluation of 
toxicity, and QoL. PFS was determined by the participating 
investigators. An independent determination of PFS conducted 
by outside reviewers was not performed.
The sample size of 50 patients for each group was 
based on an expected increase in median PFS time from 4 to 6 
FIGURE 1.   Study design for the current study.
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months for the six-cycle regimen. For the three-cycle regimen, 
at least a 4-month PFS time was hypothesized, comparable 
to the historical PFS for standard chemotherapy regimens (3 
months). The study had 88% power, with one-sided signifi-
cance level of 5%, to detect an increase of 50% in median PFS 
time (from 4 to 6 months) based on a 6-month accrual time 
and an 18-month follow-up time. This sample size also pro-
vided 82% power for a 50% increase in OS (from 7.4 to 11.1 
months), using an historical range of 6 to 8.8 months.16
Efficacy analyses were performed on an intent-to-treat 
(ITT) population, at a 0.05 significance level. The primary end 
point analysis was enumerative within each study arm, not 
comparative between arms. Although comparisons between 
treatment arms were conducted, the study was not powered to 
demonstrate an effect.
Distributions of PFS and OS times were estimated 
using the Kaplan–Meier product-limit method. The median 
time to event along with two-sided 95% confidence intervals 
(CIs) were calculated for each treatment arm. Log-rank and 
Wilcoxon tests were used for an exploratory analysis of treat-
ment arm comparison. A Cox proportional hazards model was 
used to estimate the overall hazard ratio (HR) and its 95% CI. 
Two-sided 95% CIs were calculated for the objective RRs.
QoL analyses were performed for the FACT-LCS. The 
comparability of baseline scores between treatment groups 
was assessed using a Wilcoxon rank sum test. The symp-
tom RR was analyzed using the population of randomized 
patients who completed the LCS questionnaire at baseline and 
whose baseline LCS scores were 26 or lesser. The unstratified 
Cochran-Mantel-Haensel test was used to compare symptom 
RRs between treatment arms. Lung cancer symptom scores 
were compared between treatment groups through symptom 
RR and time to symptomatic progression. The analysis of time 
to symptomatic progression was based on the population of 
randomized patients who completed the LCS questionnaire 
at baseline. Time to symptomatic progression was compared 
using an unstratified log-rank test. Analysis of the lung cancer 
symptoms using the FLSI-12 was exploratory.
RESULTS
Patient Characteristics
A total of 121 patients at 32 sites in the United States were 
enrolled in the study, which was carried out from January 5, 
2007, to December 23, 2010. All the 121 patients were randomly 
assigned to treatment (six-cycle arm: 60; three-cycle arm: 61) 
and comprised the ITT population. The majority of the patients 
were white (87.6%) and men (57.0%), with a median age of 64.0 
years (Table 1). The majority of the ITT patients had a histologi-
cal diagnosis of adenocarcinoma (78.5%), stage IV disease at 
diagnosis (80.2%), and a smoking history (either current or past) 
(90.1%). The median time from diagnosis to informed consent 
was 0.6 months for both the treatment arms. Overall, the base-
line characteristics were balanced between the treatment arms 
and generally consistent with the characteristics of a patient pop-
ulation that is receiving first-line therapy for NSCLC, with the 
one exception of a slightly higher proportion of female patients 
in this study than in the general patient population.
Drug Administration
The total number of patients who received at least one 
dose of cetuximab was 116 (58 patients per treatment arm). 
The median number of cycles received was 6.0 for each treat-
ment arm (range, 1–6). Forty-eight patients (82.8%) on the 
six-cycle arm received three courses of paclitaxel–carboplatin 
versus 43 patients (74.1%) on the three-cycle arm. Six courses 
of paclitaxel–carboplatin were administered to 37 patients 
(63.8%) on the six-cycle arm, and three patients (5.2%) 
received six courses of paclitaxel–carboplatin despite being 
assigned to the three-cycle arm. A total of 37 patients (63.8%) 
in the six-cycle arm and 35 patients (60.3%) in the three-cycle 
TABLE 1.  Baseline Patient Demographics and Disease 
Characteristics (n = 121)
Parameters
Six-cycle 
arm (n = 60)
Three-cycle 
arm (n = 61)
Total  
(n = 121)
Sex, n (%)
 Female 25 (41.7) 27 (44.3) 52 (43.0)
 Male 35 (58.3) 34 (55.7) 69 (57.0)
Age
 Mean (standard deviation),  
years
63.4 (11.52) 62.1 (8.97) 62.8 (10.29)
 Median (range), years 63.5 (32–83) 64.0 (39–81) 64.0 (32–83)
 <65, n (%) 31 (51.7) 32 (52.5) 63 (52.1)
 ≥65, n (%) 29 (48.3) 29 (47.5) 58 (47.9)
 <70, n (%) 41 (68.3) 51 (83.6) 92 (76.0)
 ≥70, n (%) 19 (31.7) 10 (16.4) 29 (24.0)
Ethnicity, n (%)
 White 53 (88.3) 53 (86.9) 106 (87.6)
 Black 2 (3.3) 4 (6.6) 6 (5.0)
 Asian 1 (1.7) 2 (3.3) 3 (2.5)
 Hispanic 3 (5.0) 0 (0.0) 3 (2.5)
 Other 1 (1.7) 2 (3.3) 3 (2.5)
ECOG performance status, n (%)
 0 24 (40.0) 29 (47.5) 53 (43.8)
 1 28 (46.7) 27 (44.3) 55 (45.5)
 Missing/unknown 8 (13.3) 5 (8.2) 13 (10.7)
Smoking status, n (%)
 Ever-smoker (current/past) 54 (90.0) 55 (90.2) 109 (90.1)
 Nonsmoker 6 (10.0) 5 (8.2) 11 (9.1)
 Missing 0 (0.0) 1 (1.6) 1 (0.8)
Pathological diagnosis, n (%)
 Nonsquamous 60 (100.0) 61 (100.0) 121 (100.0)
 Adenocarcinoma 46 (76.7) 49 (80.3) 95 (78.5)
 Large cell carcinoma 5 (8.3) 2 (3.3) 7 (5.8)
 All other diagnoses 9 (15.0) 10 (16.4) 19 (15.7)
Disease stage at diagnosis, n (%)
 I-II 1 (1.7) 1 (1.6) 2 (1.7)
 IIIA 0 (0.0) 1 (1.6) 1 (0.8)
 IIIB 9 (15.0) 6 (9.8) 15 (12.4)
 IV 47 (78.3) 50 (82.0) 97 (80.2)
 TNM incomplete 3 (5.0) 3 (4.9) 6 (5.0)
ECOG, Eastern Cooperative Oncology Group; TNM, tumor, node, metastasis 
staging.
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arm completed at least six cycles of double antibody therapy. 
Four patients (6.9%) in the six-cycle arm and three patients 
(5.2%) in the three-cycle arm had cetuximab reductions.
Efficacy
The study met its primary efficacy end point by dem-
onstrating prolonged median PFS in the six-cycle arm of at 
least 6 months: the median PFS time was 6.05 months (95% 
CI: 5.65, 7.03) in the six-cycle arm and 4.50 months (95% CI: 
4.01, 5.42) in the three-cycle arm (Fig. 2). Although the study 
was not designed or powered to demonstrate a comparative 
effect between treatment arms, the estimated treatment effect 
HR was 0.69 (95% CI: 0.47, 1.01; log-rank p = 0.0555).
OS time was similar for both the treatment arms (Fig. 3), 
and also met the predefined threshold of 11.1 months: the 
median OS time was 12.06 months (95% CI: 9.40, 19.25) in 
the six-cycle arm and 11.63 months (95% CI: 6.64, 17.61) in 
the three-cycle arm. Although the study was not designed or 
powered to demonstrate a comparative treatment effect, the 
estimated treatment effect HR was 0.94 (95% CI: 0.62, 1.43; 
log-rank p = 0.7664).
The tumor RR (CR + PR) was 51.7% (95% CI: 39.0, 
64.3) in the six-cycle arm and 44.3% (95% CI: 31.8, 56.7) in 
the three-cycle arm (odds ratio = 1.35; 95% CI: 0.66, 2.75; 
log-rank p = 0.4688). The disease control rate (CR + PR + 
stable disease) was 78.3% (95% CI: 67.9, 88.8) in the six-
cycle arm and 73.8% (95% CI: 62.7, 84.8) in the three-cycle 
arm (p = 0.6710). The median duration of response was 4.86 
months (95% CI: 4.30, 7.16) in the six-cycle arm, and 3.94 
months (95% CI: 2.92, 4.47) in the three-cycle arm (HR = 
0.57; 95% CI: 0.33, 0.97; log-rank p = 0.0350).
EGFR immunohistochemical expression was tested 
for 34 patients (56.7%) in the six-cycle arm (detected in 28 
patients) and 35 patients (57.4%) in three-cycle arm (detected 
in 29 patients) at baseline. EGFR-expressing cells were 
undetectable in 12 patients (six patients per arm) and missing 
in 52 patients (26 patients per arm). In view of the fact that 
EGFR expression data were not available for more than 40% 
of the patients in this relatively small study, EGFR expression 
data were not analyzed in relation to outcomes.
Health Outcomes
At baseline, 87 of 121 eligible patients (71.9%) (six-
cycle arm: 43; three-cycle arm: 44) completed the 36 item 
FACT-L QoL tool, and 88 of 121 eligible patients (72.7%) 
(six-cycle arm: 44; three-cycle arm: 44) completed the 
FIGURE 2.   Kaplan–Meier distribution of investigator-assessed progression-free survival by treatment in the intent-to-treat 
population.
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seven-item lung cancer symptom scale component (FACT-
LCS) of the FACT-L and the 21-item TOI component of the 
FACT-L. There was no difference between treatment arms 
in baseline FACT-LCS scores or TOI scores. The baseline 
mean FACT-L total score and the subscale emotional well-
being score were different between treatment arms (100.53 
versus 90.18 [p = 0.0021] and 17.25 versus 14.82 [p = 
0.0032], respectively).
Comparison between the six-cycle versus the three-
cycle arms revealed no significant differences in the change 
from baseline for FACT-LCS or TOI scores. For the total 
FACT-L scores, there were no differences. There was a dif-
ference for a single parameter, the physical well-being score 
(−4.81 versus 0.44; p = 0.0304).
Safety
One hundred sixteen patients received at least one dose 
of cetuximab and were evaluable for safety; five patients who 
were randomly assigned but did not receive study therapy 
were not included in the safety analysis.
Maximum grade 3/4 adverse events (AEs) possibly 
related to cetuximab were reported for 24 patients (41.1%) in 
the six-cycle arm and 23 patients (39.7%) in the three-cycle 
arm. There were no significant differences between treatment 
arms in any individual possibly cetuximab-related grade 3/4 
toxicity (Table 2).
A total of 13 patients (22.4%) in the six-cycle arm and 
eight patients (13.8%) in the three-cycle arm had one or more 
possibly cetuximab-related serious AE (SAE). Cetuximab-
related SAEs reported in at least two patients were dehydra-
tion (six-cycle arm: 3.4%; three-cycle arm: 1.7%), diarrhea 
(3.4%; 1.7%), hypersensitivity (1.7%; 3.4%), anaphylactic 
reaction (3.4%; 0%), deep vein thrombosis (1.7%; 1.7%), 
nausea (1.7%; 1.7%), and vomiting (1.7%; 1.7%).
Twelve patients (20.7%) in the six-cycle arm and 11 
patients (19.0%) in the three-cycle arm discontinued study 
therapy because of one or more AEs. The most frequent SAEs 
causing discontinuation from study treatment were hypersen-
sitivity (one patient [1.7%] in the six-cycle arm, two patients 
[3.4%] in the three-cycle arm), pulmonary embolism (two 
patients [3.4%] in the three-cycle arm), myocardial infarction 
(one patient each [1.7%]), and respiratory failure (one patient 
each [1.7%]). Two deaths (3.4%) in the six-cycle arm and five 
deaths (8.6%) in the three-cycle arm occurred becaused of 
AEs during the study or within 30 days of discontinuation. 
AEs leading to the seven deaths were one case each of intes-
tinal perforation and sepsis in the six-cycle arm, and acute 
respiratory distress syndrome/respiratory failure, pneumonia, 
FIGURE 3.   Kaplan–Meier distribution of overall survival by treatment in the intent-to-treat population.
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metastases to meninges, diabetic complication, and respira-
tory distress in the three-cycle arm.
Postdiscontinuation Therapy
A total of 63.3% of patients in the six-cycle arm and 
63.9% in the three-cycle arm received at least one postdis-
continuation anticancer therapy. The most common post-
discontinuation therapies in both the arms were systemic 
therapy (chemotherapy [six-cycle arm: 56.7%; three-cycle 
arm: 54.1%] and targeted therapy [six-cycle arm: 43.3%; 
three-cycle arm: 45.9%]) and other radiation (six-cycle arm: 
10.0%; three-cycle arm: 13.1%). The most common postdis-
continuation agents used were pemetrexed, bevacizumab, car-
boplatin, and erlotinib. There were no significant differences 
across arms in the types of postdiscontinuation systemic ther-
apies administered.
DISCUSSION
This randomized phase II study met its primary efficacy 
PFS end points. The six-cycle arm achieved a median PFS of 6 
months, whereas the median PFS was 4 months for the three-
cycle regimen. Of note, whereas the PFS was longer in the six-
cycle arm of the study than in the three-cycle arm, the OS was 
similar for both the arms (approximately 12 months) and was 
longer than anticipated. The reason that superior PFS did not 
translate into superior survival with the six-cycle regimen is not 
clear. A possible explanation includes imbalance in follow-up 
therapy. However, this does not appear to be the case because 
the type or frequency of subsequent treatments were similar for 
both the arms. Another possibility is that the variability involved 
in determining the point of disease progression resulted in 
overestimation of the PFS for the six-cycle regimen. In previous 
trials comparing three versus six cycles of chemotherapy, there 
were no significant differences for PFS or OS.
The unique and nonoverlapping toxicities of cetuximab 
and bevacizumab combined with the theoretical advantages of 
modulating two distinct molecular pathways relevant to cancer 
biology were the impetus for this study. Although the prespec-
ified study end points were met, it remains to be elucidated 
whether the prolongation in PFS coupled with an acceptable 
safety profile for each arm can be replicated in larger trials. 
Although cross-study comparisons should be performed with 
caution, the median PFS reported when both biologics were 
added to six cycles of chemotherapy was consistent with, but 
not longer than, PFS observed in phase III studies of bevaci-
zumab.3,17 Nevertheless, these data suggest that dual-biologic 
therapy in combination with cytotoxic chemotherapy is feasi-
ble and tolerated in the first-line treatment of NSCLC. This is 
in contrast to the observations from chemotherapy plus beva-
cizumab and anti-EGFR monoclonal antibody (cetuximab or 
panitumumab) in the first-line treatment of metastatic colorec-
tal cancer,18,19 in which outcomes were worse for patients on 
dual-biologic therapy compared with bevacizumab alone 
combined with chemotherapy.
In this study, the coupling of dual-biologic therapy to 
three cycles of chemotherapy led to an overall median survival 
that was similar to that seen with six cycles of therapy (11.63 
and 12.06 months, respectively). The hypothesized median 
OS results per the protocol were 7.4 months for the three-
cycle arm and 11.1 months for the six-cycle arm. It could be 
speculated that the addition of dual biologics to standard che-
motherapy has some beneficial effect on OS, allowing for a 
reduction of the number of chemotherapy cycles. However, 
this hypothesis would require further study. Although no firm 
conclusions can be drawn, these results suggest that a reduced 
number of chemotherapy cycles could be appropriate for a 
subset of patients who are less likely to tolerate more pro-
longed therapy with such agents, when targeted agents such as 
bevacizumab and cetuximab are administered in combination 
with the chemotherapy regimen.
In terms of safety, there were no significant differences 
between treatment arms in any individual possibly cetuximab-
related grade 3/4 toxicity, and there were no significant dif-
ferences between treatment arms in the number of deaths on 
therapy and within 30 days of discontinuation. A similar num-
ber of patients discontinued therapy due to AEs, consistent 
with the underlying disease and the known safety profiles for 
cetuximab, bevacizumab, paclitaxel, and carboplatin.3,6
Health outcomes results based on FACT-LCS, FACT-L, 
and TOI scores showed no consistent differences between the 
treatment arms at each cycle and no consistent changes from 
baseline. In each treatment arm, patients did not appear to 
experience a change in lung cancer symptoms or QoL over 
the course of combination therapy. No apparent differences 
between treatment arms in symptom response or progression 
were observed during the study.
In conclusion, this study met its primary PFS end point 
and also demonstrated acceptable toxicity with paclitaxel 
and carboplatin combined with the dual-biologic therapy of 
TABLE 2.  Summary of Maximum Possibly Cetuximab-Related 
CTCAEsa
MedDRA Preferred Term
Six-cycle arm  
(n = 58) n (%)
Three-cycle arm  
(n = 58) n (%)
All gradesb
Grades 
3/4
All  
gradesb
Grades  
3/4
Dermatitis acneiform 45 (77.6) 4 (6.9) 40 (69.0) 5 (8.6)
Fatigue 18 (31.0) 8 (13.8) 15 (25.9) 3 (5.2)
Hypomagnesemia 18 (31.0) 3 (5.2) 11 (19.0) 0 (0.0)
Diarrhea 12 (20.7) 3 (5.2) 12 (20.7) 3 (5.2)
Nausea 13 (22.4) 3 (5.2) 8 (13.8) 1 (1.7)
Acute respiratory distress 
syndrome
0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0)
Lung infiltration 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0)
Metastases to meninges 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0)
Respiratory failure 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0)
Sepsis 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0)
Bold text indicates p < 0.05 between treatment arms (all grades and grades 3/4). The 
all-grades p value was analyzed using an ordinal-based χ2 test. The grade 3/4 p value was 
analyzed using Fisher’s exact test.
a Includes events that were considered possibly, probably, or definitely/certainly 
related to cetuximab as judged by the investigator occurring in 5% or more patients in 
either treatment arm, with corresponding maximum.
b All grades includes grades 1–5.
CTCAE, Common Terminology Criteria for Adverse Events (version 3.0); 
MedDRA, Medical Dictionary for Regulatory Activities.
Source: Medical Dictionary for Regulatory Activities (version 13.0).
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cetuximab and bevacizumab. The full risk–benefit assess-
ment of this combination awaits the completion of the ongo-
ing Southwest Oncology Group phase III trial (S0819) that is 
evaluating paclitaxel–carboplatin–bevacizumab with or with-
out cetuximab. Finally, additional progress will likely require 
the development of biomarkers and the identification of sub-
sets of patients for whom the four-drug regimen may be par-
ticularly beneficial.
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